Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 14/20 | 0.43 |
| ▸ | PPARD | Q03181 | 5/20 | 0.39 |
| ▸ | TBXAS1 | P24557 | 2/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.37 |
| ▸ | PPARG | P37231 | 4/20 | 0.37 |
| ▸ | P2RY14 | Q15391 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2819490 | 0.93 | PPARA (0.45) | PPARAPPARDTBXAS1NPC1ALDH1A1 | |
| SCHEMBL2820111 | 0.93 | PPARA (0.43) | PPARAPPARDTBXAS1PPARG | |
| SCHEMBL2821377 | 0.91 | PPARA (0.46) | PPARAPPARDTBXAS1PPARG | |
| SCHEMBL2821242 | 0.86 | PPARA (0.46) | PPARAPPARDTBXAS1PPARG | |
| SCHEMBL2821806 | 0.86 | PPARA (0.46) | PPARAPPARDTBXAS1PPARG | |
| SCHEMBL2819539 | 0.86 | PPARA (0.41) | PPARAPPARDTBXAS1ALDH1A1PPARG | |
| SCHEMBL2819548 | 0.85 | PPARA (0.56) | PPARAPPARDPPARG | |
| SCHEMBL2824760 | 0.85 | PPARA (0.46) | PPARAPPARDTBXAS1MAPTPPARG | |
| SCHEMBL2820585 | 0.85 | PPARG (0.44) | PPARAPPARDLMNAMAPTPTGDR2 | |
| SCHEMBL2826192 | 0.84 | PPARA (0.52) | PPARAPPARDPPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100184815-A1 | AGONISTS OF PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR-ALPHA | MPM ASSET MANAGEMENT INVESTORS 2002 BVIII LLC | 2010-07-22 | — | — | US | claimed |
| WO-2010071813-A1 | AGONISTS OF PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR-α | ARYX THERAPEUTICS, INC. (US) | 2010-06-24 | — | — | WO | claimed |
| US-20100184815-A1 | AGONISTS OF PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR-ALPHA | MPM ASSET MANAGEMENT INVESTORS 2002 BVIII LLC | 2010-07-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100184815-A1 | AGONISTS OF PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR-ALPHA | PPARA, PPARD, PPARG | PPARA 1/4885PPARD 2/4885TBXAS1 444/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.